described a bovine serum albumin (BSA)/ferritin-based nanoagonist incorporating Mn2+, which could activate cGAS-STING signaling in dendritic cells (DCs) to elicit robust adaptive anti-tumor immunity. Mn2+ could enhance the sensitivity of cGAS to dsDNA and augment STING signaling, which could further enhance the tumor-specific T cell-mediated immune response against poorly immunogenic solid tumors in vivo, offering a robust approach for immunotherapy in the clinics. This evidence concerns the gene STING1 and neoplasm.